Posted by Michael Wonder on 19 Apr 2018
US FDA approves Tagrisso as first-line treatment for EGFR-mutated non-small cell lung cancer
18 April 2018 - Tagrisso delivered unprecedented median progression-free survival of 18.9 months versus 10.2 months compared with current standard of care.
AstraZeneca today announced that the US FDA has approved Tagrisso (osimertinib) for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumours have epidermal growth factor receptor (EGFR) mutations, (exon 19 deletions or exon 21 L858R mutations), as detected by an FDA-approved test.
The approval is based on results from the Phase III FLAURA trial, which were presented at the European Society of Medical Oncology 2017 Congress and published in the New England Journal of Medicine.
